|title=TTFields / Optune Lua for Mesothelioma: STELLAR Trial, FDA Approval & Treatment Guide
...herapy using Optune Lua for malignant pleural mesothelioma. Covers STELLAR trial results (18.2-month median OS), FDA HDE approval, mechanism of action, trea
...
64 KB (8,231 words) - 09:57, 6 April 2026
...and pembrolizumab plus chemotherapy. Five-year data from the CheckMate 743 trial, published in February 2026, confirmed that immunotherapy more than doubles
...trating a mean survival advantage of 7 months for P/D. However, the MARS 2 trial raised fundamental questions about the benefit of surgery at all, finding t
...
55 KB (6,918 words) - 12:35, 6 April 2026
|keywords=mesothelioma chemotherapy, cisplatin pemetrexed, EMPHACIS trial, carboplatin mesothelioma, chemoimmunotherapy, second-line chemotherapy, pe
...adding:8px; border-bottom:1px solid #dee2e6; font-weight:bold;" | EMPHACIS Trial Response Rate
...
48 KB (5,851 words) - 22:11, 8 March 2026
..., and [[Dr_Paul_Baas|Dr. Paul Baas]]'s [[CheckMate_743_Trial|CheckMate 743 trial]] that established immunotherapy as the new standard of care in 2020.<ref n
* '''Surgery evolved from radical to conservative''' — The 2011 MARS trial showed extrapleural pneumonectomy offered no survival benefit, validating D
...
38 KB (4,755 words) - 03:42, 9 March 2026
...72% with 2 complete metabolic responses (Memorial Sloan Kettering Phase I trial); Phase II ongoing<ref name="nci" />
...the most dramatic benefit from '''immunotherapy''' — in the CheckMate 743 trial, nivolumab plus ipilimumab more than doubled median survival compared to ch
...
59 KB (7,425 words) - 01:11, 6 April 2026
'''Immunotherapy Access:''' The CheckMate 743 trial demonstrated that nivolumab plus ipilimumab achieves median overall surviva
...ge treatments with rigorous monitoring. Both CheckMate 743 and the STELLAR trial (TTFields) demonstrated meaningful survival improvements over standard care
...
41 KB (5,121 words) - 20:56, 8 March 2026
* '''The average trial verdict exceeds the average settlement by 15-fold''' — jury awards averaged
...izumab to chemotherapy boosted 3-year survival by 47%''' — the KEYNOTE-483 trial (n=440) achieved 25% 3-year overall survival versus 17% with chemotherapy a
...
62 KB (7,831 words) - 01:11, 6 April 2026
* [[Trial Preference|Trial Preference]]
...othelioma makes expedited legal action essential. Many jurisdictions offer trial preference or expedited scheduling for terminally ill plaintiffs, and famil
...
216 KB (26,444 words) - 23:30, 23 January 2026
